Communiqués de presse Novartis Santé & sciences de la vie — Flux RSS et veille en direct
PPN World indexe les communiqués de presse de Novartis et en archive chaque publication. Ce fil est silencieux depuis le 21 juillet 2026 — ses 21 communiqués indexés restent consultables, et une alerte vous préviendra dès qu'il publiera de nouveau.
URL du flux RSS de Novartis
https://hpampthnhbmgpdxezfop.supabase.co/functions/v1/scrape-config?config=novartis-com-media-releasesÀ propos de ce fil
Novartis fait partie des 1200+ fils de presse que PPN World surveille en continu — un fil en anglais axé sur le secteur Santé & sciences de la vie, classé sous « Suisse » dans notre index par pays. Chaque communiqué est dédupliqué, géolocalisé et enrichi d'un résumé IA, et vous pouvez y attacher des alertes sur recherches enregistrées. Le communiqué le plus récent de notre index a été publié le 21 juillet 2026; le fil est silencieux depuis.
Comment suivre les communiqués de Novartis
- Copiez l'URL du flux RSS de Novartis affichée ci-dessus.
- Collez-la dans n'importe quel lecteur RSS (Feedly, Inoreader, NetNewsWire…) pour recevoir le flux brut.
- Ou suivez Novartis dans PPN World pour ajouter déduplication, alertes sur recherches enregistrées et résumés IA sur les 1200+ fils.
Communiqués de Novartis — archives
- Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmedil y a 9 j
Ad hoc announcement pursuant to Art. 53 LRSecond quarterNet sales grew +1% (cc1, +3% USD), with core operating income1 flat (cc and USD)Sales growth driven by priority brands including Kisqali (+43%…
- Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus; Prognose für das Geschäftsjahr bekräftigtil y a 9 j
Ad-hoc-Mitteilung gemäss Art. 53 KRZweites QuartalDer Nettoumsatz stieg um +1% (kWk1, +3% USD), das operative Kernergebnis1 blieb unverändert (kWk und USD)Das Umsatzwachstum beruhte auf den…
- Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgANil y a 13 j
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks,…
- Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patientsil y a 24 j
Adds potential first-in-class, N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads Strengthens the Novartis…
- Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)il y a 28 j
First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults Fixed, one-time dose designed to replace the faulty SMN1 gene,…
- Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)il y a 48 j
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable safety profile and no observed liver safety…
- Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpointil y a 49 j
Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous…
- Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026il y a 52 j
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentationNew Phase IIIb REMIXED…
- Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 yearsil y a 56 j
Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with Vanrafia vs placebo, based on supportive eGFR slope analysis1Vanrafia reduced protein in urine by 38.3% vs…
- Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patientsil y a 57 j
Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid use; safety consistent with established Cosentyx profile1,…
- Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CMLil y a 59 j
Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs1 Clinically relevant 15.2%…
- Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseasesil y a 59 j
New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral sessionNew ianalumab interim results from Sjögren’s Phase III…
Les plus récents communiqués de ce fil défilent en direct pour les membres PPN World.
Questions fréquentes
Comment suivre les communiqués de Novartis en temps réel?+
Existe-t-il un flux RSS pour Novartis?+
Quelle est l'URL du flux RSS de Novartis?+
Quel type de communiqués Novartis publie-t-il?+
Fils liés
- Presseportal (Schweiz)
- Presseportal Schweiz (PPS)
- Swiss-Press.com (HELP Media)
- République et canton de Genève — Communiqués et publications
- Stadt Zürich — Medienmitteilungen
- Kanton Bern Medienmitteilungen
- Swiss National Bank
- EPFL News
- Kanton Graubünden — Medienmitteilungen Standeskanzlei
- Ville de Genève — Actualités